Aurinia to expand renal franchise with novel indications and launches development program
Aurinia announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease. Aurinia also announced plans to evaluate its proprietary nanomicellar VOS for treatment of keratoconjunctivitis sicca or dry eye syndrome. October 20, 2017